Composition and method for treating acute respiratory tract infections
AssigneeGlycom A/S
InventorsBruce McConnell, Louise Kristine Vigsnæs
Life of this patent
Estimating the term…
Abstract
A composition and method for using it to prevent and/or relieve symptoms of acute respiratory tract infections, particularly bronchitis, in immune-compromised persons, particularly adults. The composition contains 2′-fucosyllactose and lacto-N-neotetraose and/or lacto-N-tetraose.
Claims18
A method of at least one of preventing acute lower respiratory tract infection and relieving symptoms of acute lower respiratory tract infection in an adult whose immune system is absent or weakened due to a condition selected from the group consisting of human immunodeficiency virus infection (HIV), acquired immune deficiency syndrome (AIDS), chemotherapy for cancer, radiation therapy for cancer, cancer, genetic disorder, pregnancy, contraindication for anti-infection pharmaceutical medications (“immune-compromised person”), the method comprising administering to the immune-compromised person an effective dose of a composition consisting essentially of 2′-FL and at least one of LNnT and LNT, wherein the abundance of at least one of Bifidobacterium adolescentis and Bifidobacterium pseudocatenulatum in the intestine of the person is increased by the dose of 2′-FL and at least one of LNnT and LNT.
A method of preventing acute lower respiratory tract infection in an elderly adult who is not suffering from a disease and who has not consumed antibiotic drugs in the last 3 months, the method comprising daily administering to the elderly adult an effective dose of a composition consisting essentially of 2′-FL and LNnT, wherein the abundance of at least one of Bifidobacterium adolescentis and Bifidobacterium pseudocatenulatum in the intestine of the person is increased by the dose of 2′-FL and LNnT.
A method of at least one of preventing acute bronchitis and pneumonia in a pregnant woman less than 60 years old, the method comprising daily administering to the pregnant woman an effective dose of a composition consisting essentially of 2′-FL and at least one of LNT and LNnT, wherein the abundance of at least one of Bifidobacterium adolescentis and Bifidobacterium pseudocatenulatum in the intestine of the person is increased by the dose of 2′-FL and at least one of LNnT and LNT.
Dependencies are inferred from the claim text.